The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.
C. Reynolds
Consultant or Advisory Role - Pfizer
A. I. Spira
No relevant relationships to disclose
W. L. Gluck
No relevant relationships to disclose
R. E. Pluenneke
No relevant relationships to disclose
K. A. Boehm
No relevant relationships to disclose
F. Zhan
No relevant relationships to disclose
L. Asmar
No relevant relationships to disclose